Applied Biosystems推出行业首台声波聚焦流式细胞仪

Applied Biosystems推出行业第一台声波聚焦流式细胞仪

Attune™声波聚焦流式细胞仪在细胞生物学应用中拥有更胜一筹的样品通量、灵敏度、准确性和分析速度

2009年12月7日，来自美国加利福尼亚的消息——生命技术公司（纳斯达克代码：LIFE）旗下美国应用生物系统公司今日宣布它正式进入流式细胞仪市场，首次推出Attune™ 声波聚焦流式细胞仪
（Attune™Acoustic Focusing Cytometer），这是第一台用声波精确控制细胞移动的流式细胞计数系统。该公司凭借在仪器制造上的专长，再加上长期以来在流式细胞仪试剂上的领先供应商地位，创造出这种新技术新产品，让客户在一系列细胞生物学应用中得到更高的样品通量、灵敏度和准确性。

流式细胞仪的原理在于让细胞穿过激光检测设备，从而使科学家们得以对细胞进行计数和检测。每秒钟可计算数千个细胞的速度可实现对整个细胞群体的快速鉴定。流式细胞仪在细胞生物学领域的应用范围也在快速增长，包括细胞表达蛋白的研究（免疫分型）、定量细胞中的DNA、细胞计数及其它。

Attune声波聚焦流式细胞仪可帮助科学家们实现对细胞群体中大量异质细胞进行统计学数据的采集，以便研究包括大小、复杂性、表型和健康情况在内的细胞群体参数。Attune的专利技术可让科学家们获得更高的灵敏度，通过增加通量来节约时间，并可用于体积小的样品。此外，Attune在提供这些升级性能的同时，还凭借紧凑的声学技术而实现了体积小，以及开展实验所需的消耗品量更少等优势。这些独特的特征将有助于实现传统细胞仪系统所无法实现的科研应用，从样品分离制备到微珠为基础的样品分析。

生命科技公司细胞系统的总裁Nicolas Barthelemy 表示： “Attune技术将某些实验的时间缩短了一个数量级并大大提高了灵敏度，从而加速了研究流程。”“这种独特仪器的推出，正是生命技术公司综合利用世界顶级仪器制造经验和细胞生物学上的专长，为生命科学研究者推出创新技术方案的又一范例。此仪器非常适合细胞信号分析和灵敏度极其重要的稀有细胞学应用，它也是各种细胞分析实验室的极好补充。”

生命科技公司流式细胞仪的主管Mike Olszowy表示：“在流式细胞仪方面，声学聚焦技术同时实现了更长的通过时间和更高的通量，因而能够在对样品中每一个细胞进行更好分析的同时对更大量的细胞进行分析。Attune的推出使得生命科技公司朝着‘数字生物学’的蓝图又迈进了一步，凭借‘数字生物学’科学家们将跨越异质细胞混合群体的整体分析而推进到在单细胞水平对分子表型进行更为精确的定量分析。”

生命科技公司（纳斯达克代码：LIFE）是一家致力于改善人类环境的全球生物技术公司。我们的仪器、耗材和服务能让研究者加速科学探索与开发，让生命变得更美好。我们的客户在生物学领域努力工作，不断加速个性化药物、再生科学、分子诊断、农业和环境研究以及21世纪的法医鉴定。公司2008年的销售额超过30亿，全球雇员达9500人，分布在100多个国家，并拥有3600多项知识产权专利及专有许可证。生命科技公司由Invitrogen公司和应用生物系统公司合并而成。更多关于我们如何起作用的信息，请访问网站http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2 www.lifetechnologies.com&esheet=6114661&lan=en_US&anchor www.lifetechnologies.com&index=1&md5=72d77b8670b362b20a1b9b112bbd708f。在Facebook和Twitter上追随生命科技公司（@LIFECorporation）。

本新闻稿包含前瞻性声明，涉及带有风险与不确定性的预期结果。本新闻稿中所包含的某些信息，包括但不限于，行业趋势和生命科技公司的计划、目标、预期和其商业策略的陈述，可能导致的实际结果与前瞻性声明中明示或暗示的风险和不确定性将存在差异。任何声明都不是历史事实的陈述，而是前瞻性声明。在措辞上，使用“相信”、“计划”、“试图”、“预期”、“制定目标”、“估计”、“期望”等，并/或使用将来时或条件结构句（“将”、“可能”、“能够”、“应该”等），或类似的表述可分辨出某些前瞻性声明。那些可能导致实际结果与这些前瞻性声明中的描述大相径庭的重要因素，在生命科技公司提交给美国证券交易委员会的各种文件中有详细说明。生命科技公司不承担更新或修订任何前瞻性声明的义务，以反映后期事件或环境。

来源：生命科技公司

Applied Biosystems Debuts Industry's First Acoustic Flow Cytometer

CARLSBAD, Calif., Dec 07, 2009 (BUSINESS WIRE) -- Applied Biosystems, part of LifeTechnologies Corporation (NASDAQ:LIFE) today announced its entry into the flow cytometry instrumentation market with the debut of the Attune(TM) Acoustic Focusing Cytometer, a first of its kind cytometry system designed to use sound waves to precisely control the movement of cells. The company has built upon its expertise in instrumentation, as well as its position as a long-time leading provider of flow cytometry reagents, to create a technology that will offer customers enhanced sample throughput, sensitivity and accuracy for a range of cell biology applications.

Flow cytometry allows scientists to count and examine cells by passing them through a laser-based detection device. Thousands of cells per second may be counted, allowing rapid characterization of entire populations of cells. Cellular biologists engage in flow cytometry for a rapidly growing range of applications, including the study of proteins expressed by cells (immunophenotyping), quantifying the amount of DNA in cells, cell counting, among others.

Attune enables scientists to gather statistical data on a large number of heterogeneous cells to study parameters within a cell population, including size, complexity, phenotype and health. Attune's proprietary technology allows scientists to achieve enhanced sensitivity, saves time by increasing throughput, and can be used with small sample sizes. In addition, it offers these enhanced capabilities with a reduced footprint due to the compact acoustic technology and the far smaller volume of consumables required to perform an experiment. These unique capabilities will enable scientific applications not previously possible on traditional cytometry systems, ranging from sample preparation to bead-based analyses.

"The Attune technology will accelerate research workflows by reducing the time of some experiments by an order of magnitude with greatly increased sensitivity," said Nicolas Barthelemy, President of Cell Systems at Life Technologies. "The introduction of this unique instrument is another example of how Life Technologies is using its expertise in both world-class instrumentation and cell biology to create an innovative solution for life science researchers. This instrument is ideally suited for cell signaling and rare event applications where sensitivity is critical and is a great addition to any cellular analysis laboratory."

"In flow cytometry, acoustic focusing enables both longer transit times and higher throughput, which simultaneously permits better interrogation of every cell in a sample as well as the analysis of much larger numbers of cells," said Mike Olszowy, Head of Flow Cytometry at Life Technologies. "The introduction of Attune brings Life Technologies one step closer to its vision of 'Digital Biology' whereby scientists can move beyond ensemble measurements of heterogeneous mixtures to a more precise quantitation of molecular phenotypes at the single cell level."

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2 www.lifetechnologies.com&esheet=6114661&lan=en_US&anchor www.lifetechnologies.com&index=1&md5=72d77b8670b362b20a1b9b112bbd708f. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

SOURCE: Life Technologies Corporation